Share on StockTwits

Shares of Smith & Nephew plc (LON:SN) have received an average recommendation of “Hold” from the nineteen brokerages that are currently covering the stock, AR Network reports. Two investment analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is GBX 969 ($16.45).

Shares of Smith & Nephew plc (LON:SN) traded down 1.34% on Wednesday, hitting GBX 1028.00. 665,500 shares of the company’s stock traded hands. Smith & Nephew plc has a 52 week low of GBX 737.50 and a 52 week high of GBX 1136.00. The stock has a 50-day moving average of GBX 1047. and a 200-day moving average of GBX 954.9. The company’s market cap is £9.180 billion.

A number of research firms have recently commented on SN. Analysts at Credit Suisse raised their price target on shares of Smith & Nephew plc from GBX 865 ($14.69) to GBX 890 ($15.11) in a research note on Wednesday. They now have a “neutral” rating on the stock. Separately, analysts at Sanford C. Bernstein reiterated an “outperform” rating on shares of Smith & Nephew plc in a research note on Friday, July 25th. They now have a GBX 1,160 ($19.70) price target on the stock. Finally, analysts at BNP Paribas reiterated an “outperform” rating on shares of Smith & Nephew plc in a research note on Thursday, July 24th. They now have a GBX 1,250 ($21.23) price target on the stock.

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.